NCT01482949View on ClinicalTrials.gov

A Rollover Protocol for Subjects Previously Treated With AGS-003

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions

Renal Cell Carcinoma

Interventions

DRUG

AGS-003

Autologous Dendritic Cell Immunotherapy

Trial Locations (1)

55455

University of Minnesota Cancer Center, Minneapolis

Sponsors

Lead Sponsor

Argos Therapeutics

All Listed Sponsors

lead

Argos Therapeutics

INDUSTRY

NCT01482949 - A Rollover Protocol for Subjects Previously Treated With AGS-003 | Biotech Hunter | Biotech Hunter